Clinical Trials Logo

Bardet-Biedl Syndrome clinical trials

View clinical trials related to Bardet-Biedl Syndrome.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT05183802 Approved for marketing - Obesity Clinical Trials

An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)

Start date: n/a
Phase:
Study type: Expanded Access

An open-label, single-arm, multicenter, Expanded Access Protocol [EAP] designed to provide treatment access to setmelanotide (3 mg, administered subcutaneously [SC], once daily) for eligible patients with BBS who have no alternative treatment options. All patients will continue to receive setmelanotide at the discretion of the Treating Physician and while they are deriving clinical benefit.